Iclaprim

Drug Profile

Iclaprim

Alternative Names: AR-100; MTF-100; Ro-48-2622

Latest Information Update: 28 Apr 2017

Price : $50

At a glance

  • Originator Roche
  • Developer Arpida; Evolva Holding SA; Motif Bio
  • Class Antibacterials; Pyrimidines; Small molecules
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Skin and soft tissue infections
  • Phase I Nosocomial infections
  • Suspended Nosocomial pneumonia
  • Discontinued Chlamydial infections; Gonorrhoea

Most Recent Events

  • 18 Apr 2017 Motif announces intention to submit IND for iclaprim in Skin-and-soft-tissue-infections in 2018
  • 18 Apr 2017 Topline efficacy and adverse events data from a phase III trial in Skin-and-soft-tissue-infections released by Motif
  • 30 Jan 2017 Motif Bio completes the phase III REVIVE-1 trial for Skin and soft tissue infections in USA, Bulgaria, Germany, Latvia, Colombia, Peru, Puerto Rico, Ukraine, Chile and Poland (IV) (NCT02600611)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top